Publications by authors named "Mitchell DeKoven"

Claim this Profile
A
Antifungal therapy patterns, healthcare utilization, costs, and mortality in central nervous system and non-central nervous system disseminated coccidioidomycosis across the continuum-of-care.
Fariba Donovan, Mark Bresnik, Belinda Lovelace, Lia Pizzicato, Vamshi Ruthwik Anupindi, Mitchell DeKoven

Clin Microbiol Infect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost comparison of F(ab') and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis.
Walter Garcia-Ubbelohde, Lia Pizzicato, Keith J Boesen, Swapna Munnangi, Liucheng Shi, Mitchell DeKoven

Expert Rev Pharmacoecon Outcomes Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation.
Riddhi Doshi, Victoria Divino, Luke Greenwalt, Mitchell DeKoven

Expert Rev Pharmacoecon Outcomes Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis.
Robert J Morlock, Deepan Dalal, Victoria Divino, Mitchell DeKoven, Stephanie D Taylor

Rheumatol Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Healthcare Costs Among Patients with Stroke and Spasticity: A 2-Year Longitudinal Study.
Michael Hull, Vamshi Ruthwik Anupindi, Jing He, Mitchell DeKoven, Jumaah Goldberg

Neurol Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between the Need to Change Initial Antifungal Therapy and Treatment Costs in Patients With Invasive Aspergillosis.
Barbara D Alexander, Melissa Johnson, Mark Bresnik, Vamshi Ruthwik Anupindi, Lia Pizzicato, Mitchell DeKoven

Open Forum Infect Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Antifungal Therapy Patterns Across the Continuum of Care in United States Adults with Invasive Aspergillosis.
Barbara D Alexander, Melissa Johnson, Mark Bresnik, Vamshi Ruthwik Anupindi, Lia Pizzicato, Mitchell DeKoven

J Fungi (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program.
Katrina S Firlik, Vamshi Ruthwik Anupindi, Vincent Hayes, Mitchell DeKoven, Asif Shaikh

Expert Rev Pharmacoecon Outcomes Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023.
Mickaël Hiligsmann, Mitchell P DeKoven, Riddhi Doshi, Carolyn Gotay, Carlo Lazzaro

Expert Rev Pharmacoecon Outcomes Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Payer approval and rejection of oral anticoagulant prescriptions and prescription abandonment patterns among patients with venous thromboembolism.
Dionne M Hines, Riddhi Doshi, Vamshi Ruthwik Anupindi, Feng Dai, Cristina Russ, Mitchell DeKoven

J Manag Care Spec Pharm· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data.
Jill Dreyfus, Swapna Munnangi, Camilla Bengtsson, Bárbara Correia, Rejane Figueiredo, Mitchell DeKoven

Vaccine· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health care resource utilization and costs among patients with spasticity or cervical dystonia.
Michael Hull, Natalya Danchenko, Vamshi Ruthwik Anupindi, Mitchell DeKoven, Jing He

J Manag Care Spec Pharm· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Botulinum Toxin Utilization, Treatment Patterns, and Healthcare Costs Among Patients with Spasticity or Cervical Dystonia in the US.
Michael Hull, Vamshi Ruthwik Anupindi, Mitchell DeKoven, Jing He, Jonathan Bouchard

Adv Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative economic outcomes in patients with focal seizures initiating eslicarbazepine acetate versus brivaracetam in the long-term care setting in the USA.
Darshan Mehta, Inyoung Lee, Hangcheng Liu, Mitchell DeKoven, Brian Wensel

J Comp Eff Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies.
Stephen Jolles, B Douglas Smith, Donald C Vinh, Rajiv Mallick, Gabriela Espinoza, Mitchell DeKoven

Leuk Lymphoma· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infections in secondary immunodeficiency patients treated with Privigen or Hizentra: a retrospective US administrative claims study in patients with hematological malignancies.
Rajiv Mallick, Victoria Divino, B Douglas Smith, Stephen Jolles, Mitchell DeKoven

Leuk Lymphoma· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic benefits of BIS-aided assessment of post-BC lymphedema in the United States.
Sara P Bilir, Mitchell P DeKoven, Juliet Munakata

Am J Manag Care· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospital providers: the day after FDA approval.
Mitchell Dekoven, Brian McCagh, Jeremy Zoch

Biotechnol Healthc· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis